BRPI0921586A2 - articuladores de albumina de soro humana e conjugados destes - Google Patents

articuladores de albumina de soro humana e conjugados destes

Info

Publication number
BRPI0921586A2
BRPI0921586A2 BRPI0921586A BRPI0921586A BRPI0921586A2 BR PI0921586 A2 BRPI0921586 A2 BR PI0921586A2 BR PI0921586 A BRPI0921586 A BR PI0921586A BR PI0921586 A BRPI0921586 A BR PI0921586A BR PI0921586 A2 BRPI0921586 A2 BR PI0921586A2
Authority
BR
Brazil
Prior art keywords
articulators
conjugates
serum albumin
human serum
human
Prior art date
Application number
BRPI0921586A
Other languages
English (en)
Inventor
Huhalov Alexandra
Mcdonagh Charlotte
Feldhaus Michael
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/040259 external-priority patent/WO2009126920A2/en
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of BRPI0921586A2 publication Critical patent/BRPI0921586A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0921586A 2008-11-18 2009-10-14 articuladores de albumina de soro humana e conjugados destes BRPI0921586A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11579708P 2008-11-18 2008-11-18
PCT/US2009/040259 WO2009126920A2 (en) 2008-04-11 2009-04-10 Human serum albumin linkers and conjugates thereof
PCT/US2009/060721 WO2010059315A1 (en) 2008-11-18 2009-10-14 Human serum albumin linkers and conjugates thereof

Publications (1)

Publication Number Publication Date
BRPI0921586A2 true BRPI0921586A2 (pt) 2019-09-24

Family

ID=42198443

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921586A BRPI0921586A2 (pt) 2008-11-18 2009-10-14 articuladores de albumina de soro humana e conjugados destes

Country Status (6)

Country Link
US (4) US8927694B2 (pt)
JP (1) JP5677972B2 (pt)
KR (1) KR20110112301A (pt)
CN (1) CN102282168A (pt)
BR (1) BRPI0921586A2 (pt)
WO (1) WO2010059315A1 (pt)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
WO2008140493A2 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
EP2193146B1 (en) 2007-09-14 2016-05-25 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
BRPI0921586A2 (pt) * 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
ES2678144T3 (es) * 2010-02-16 2018-08-09 Medimmune, Llc Composiciones relacionadas con SAH y métodos de uso
EP2544680B1 (en) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
WO2011139681A1 (en) 2010-04-26 2011-11-10 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
MA34287B1 (fr) 2010-05-06 2013-06-01 Novartis Ag Compositions et méthodes d'utilisation d'anticorps multivalents thérapeutiques de faible densité de la protéine apparentée à la lipoprotéine 6 (lrp6)
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2815266C (en) 2010-11-05 2023-09-05 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
MX349057B (es) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
KR20140041396A (ko) 2010-12-06 2014-04-04 메리맥 파마슈티컬즈, 인크. 안트라사이클린 화학요법제를 포함하는 erbb2-표적 면역리포좀으로의 치료에서 심장독성을 예방하기 위한 용량 및 투여
WO2012091563A1 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
BR112013021660A2 (pt) * 2011-02-24 2018-06-12 Merrimack Pharmaceuticals Inc terapias de combinação compreendendo agentes anti-erbb3
CN103732628B (zh) 2011-03-03 2017-06-23 酵活有限公司 多价杂多聚体骨架设计和构建体
KR20140044796A (ko) * 2011-03-11 2014-04-15 메리맥 파마슈티컬즈, 인크. 호르몬 무반응 유방암의 치료에서 ｅｇｆｒ-패밀리 수용체의 저해제의 용도
EA201301025A1 (ru) 2011-03-15 2014-01-30 Мерримак Фармасьютикалс, Инк. Преодоление устойчивости к ингибиторам пути erbb
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
AU2012316859A1 (en) 2011-09-29 2014-04-17 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
CN109897103B (zh) 2011-11-04 2024-05-17 酵活英属哥伦比亚有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2013067355A1 (en) * 2011-11-04 2013-05-10 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
US20130165628A1 (en) * 2011-12-23 2013-06-27 Sri International Double Binding Constructs
US9273092B2 (en) 2011-12-23 2016-03-01 RioGin LLC Selective binding compounds
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
WO2013109994A1 (en) * 2012-01-20 2013-07-25 Sea Lane Biotechnologies, Llc Surrobody cojugates
CN104736559B (zh) 2012-03-16 2022-04-08 阿尔布梅迪克斯医疗有限公司 白蛋白变体
AU2013259053A1 (en) * 2012-05-11 2015-01-15 Merrimack Pharmaceuticals, Inc. Dosage and administration of bispecific scFv conjugates in combination with anti-cancer therapeutics
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CA2878640C (en) 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014089127A1 (en) 2012-12-03 2014-06-12 Merrimack Pharmaceuticals, Inc. Combination therapy for treating her2-positive cancers
WO2014098464A1 (ko) * 2012-12-18 2014-06-26 이화여자대학교 산학협력단 인간혈청알부민 열안정화용 조성물 및 이를 이용한 열안정화된 인간혈청알부민의 제조방법
WO2014121033A1 (en) * 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2910945A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
TWI610685B (zh) * 2013-05-13 2018-01-11 視界全球控股有限公司 用於癌症標靶治療及診斷成像之包含經修飾的基於血紅素之治療劑的醫藥組成物
CA2913363A1 (en) * 2013-05-24 2014-11-27 Zymeworks Inc. Modular protein drug conjugate therapeutic
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
HK1226308A1 (zh) 2013-08-30 2017-09-29 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
JP2016540993A (ja) 2013-09-30 2016-12-28 第一三共株式会社 タンパク質生体マーカー及びその使用
BR112016010166A2 (pt) 2013-11-11 2017-12-05 Armo Biosciences Inc métodos para usar interleucina-10 para tratar doenças e distúrbios
SMT202500227T1 (it) 2013-12-25 2025-09-12 Daiichi Sankyo Co Ltd Metodo per produrre un coniugato anticorpo anti-trop2-farmaco
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10487140B2 (en) 2014-01-14 2019-11-26 Integrated Biotherapeutics, Inc. Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
HRP20241783T1 (hr) 2014-01-31 2025-02-28 Daiichi Sankyo Company, Limited Anti-her2 antitijelo-lijek konjugat
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
KR20240042540A (ko) * 2014-02-28 2024-04-02 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
SG11201607434WA (en) 2014-04-07 2016-10-28 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
US11473080B2 (en) * 2014-04-30 2022-10-18 The Board Of Trustees Of The University Of Illinois Method for generating high affinity, bivalent binding agents for sandwich assays
EA201692287A1 (ru) 2014-05-13 2017-06-30 Чугаи Сеияку Кабушики Каиша Антигенсвязывающая молекула, перенаправляющая т-клетки на клетки, обладающие иммуносупрессорной функцией
JP6695812B2 (ja) 2014-05-14 2020-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピン及びｈｅｒ２のドメインｉｉに結合するｈｅｒ３／ｈｅｒ２二重特異性抗体
WO2015200837A1 (en) 2014-06-27 2015-12-30 Fl Therapeutics Llc Abiraterone derivatives and non-covalent complexes with albumin
WO2016022723A1 (en) 2014-08-05 2016-02-11 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
CA2970927A1 (en) * 2014-10-31 2016-05-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tlr9 targeted cytotoxic agents
SG11201705496SA (en) 2015-01-08 2017-08-30 Genmab As Bispecific antibodies against cd3 and cd20
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP6787890B2 (ja) 2015-06-29 2020-11-18 第一三共株式会社 抗体−薬物コンジュゲートの選択的製造方法
KR102786353B1 (ko) 2015-07-15 2025-03-26 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
CN112263683A (zh) * 2015-08-11 2021-01-26 同宜医药（苏州）有限公司 多配体药物偶联体及其用途
MX2018001825A (es) 2015-08-20 2018-05-07 Albumedix As Variantes y conjugados de albumina.
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
BR112018002941B1 (pt) 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
JP6933379B2 (ja) * 2015-09-24 2021-09-08 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 転移を低減するための方法および組成物
EP3355907B1 (en) 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
RS61800B1 (sr) 2015-10-23 2021-06-30 Merus Nv Vezujući molekuli koji inhibiraju rast kancera
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
KR101746152B1 (ko) 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
CA3005953A1 (en) 2015-12-22 2017-06-29 Albumedix Ltd Improved protein expression strains
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
WO2017161173A1 (en) 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
CN109641959B (zh) 2016-07-14 2023-08-22 健玛保 针对cd40和cd137的多特异性抗体
WO2018083470A1 (en) 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
TWI862473B (zh) 2016-12-12 2024-11-21 日商第一三共股份有限公司 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
TWI780104B (zh) 2017-01-17 2022-10-11 日商第一三共股份有限公司 抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途
KR20250007025A (ko) 2017-03-09 2025-01-13 젠맵 에이/에스 Pd-l1에 대한 항체
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
TWI855528B (zh) 2017-05-15 2024-09-11 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
KR102744809B1 (ko) 2017-05-17 2024-12-23 메뤼스 엔.페. 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합
DK3642343T3 (en) 2017-06-20 2022-03-14 Albumedix Ltd Improved protein expression strains
EP3661960A1 (en) 2017-08-04 2020-06-10 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
WO2019096226A1 (en) * 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy
SMT202300227T1 (it) 2018-05-18 2023-09-06 Glycotope Gmbh Anticorpo anti-muc1
IL280296B2 (en) 2018-07-27 2025-03-01 Daiichi Sankyo Co Ltd Drug recognition protein of an antibody-drug conjugate
AU2019315177A1 (en) 2018-07-31 2021-02-25 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
MX2021003234A (es) 2018-09-19 2021-07-16 Lava Therapeutics N V Inmunoglobulina de la molecula cd1d de acción dual.
SG11202104300PA (en) 2018-11-06 2021-05-28 Genmab As Antibody formulation
CN109627337B (zh) * 2018-12-29 2023-07-21 上海复宏汉霖生物技术股份有限公司 一种抗prlr的单克隆抗体及其制备方法和应用
BR112021015238A8 (pt) 2019-02-01 2022-08-16 Lava Therapeutics B V Novos anticorpos de ligação a cd40
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
CN111603567B (zh) * 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
EP3946631A1 (en) * 2019-03-26 2022-02-09 Shimadzu Corporation Photoimmunotherapy and pharmaceutical agent used therefor
WO2020237305A1 (en) * 2019-05-27 2020-12-03 Baker Heart and Diabetes Institute Binding proteins comprising the extracellular domain of cd39 and methods of treating or preventing neurological diseases
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
US20230000774A1 (en) 2019-12-04 2023-01-05 Albumedix Limited Methods and compositions produced thereby
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
ES2934984T3 (es) * 2020-02-13 2023-02-28 Orano Med Procedimiento para la modificación específica del sitio de un anticuerpo
US20210292418A1 (en) 2020-03-18 2021-09-23 Genmab A/S Antibodies
EP4133084A1 (en) 2020-04-09 2023-02-15 Autolus Limited Polypeptide
IL297986A (en) 2020-05-08 2023-01-01 Genmab As Bispecific antibodies against cd3 and cd20
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
CA3187061A1 (en) 2020-08-06 2022-02-10 Karsten Beckmann Binding agents for coronavirus s protein
KR20230066040A (ko) 2020-09-10 2023-05-12 젠맵 에이/에스 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체
MX2023002545A (es) 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes.
US20240016944A1 (en) * 2020-11-10 2024-01-18 New York University Macropinocytosis selective monobody-drug conjugates
KR20230157933A (ko) 2020-12-10 2023-11-17 라바 테라퓨틱스 엔.브이. 감마-델타 t 세포 수용체에 결합하는 항체
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
KR20230169950A (ko) 2021-02-26 2023-12-18 라바 테라퓨틱스 엔.브이. Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체
MX2023012351A (es) 2021-05-07 2023-10-31 Genmab As Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3).
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
WO2023278786A1 (en) * 2021-06-30 2023-01-05 Silver Creek Pharmaceuticals, Inc. Chimeric proteins for targeted delivery of growth factors to the glomerulus
EP4402171A1 (en) 2021-09-13 2024-07-24 Janssen Biotech, Inc. Cd33 x v delta 2 multispecific antibodies for the treatment of cancer
EP4413039A1 (en) 2021-10-08 2024-08-14 Genmab A/S Antibodies binding to cd30 and cd3
WO2023067138A1 (en) 2021-10-21 2023-04-27 LAVA Therapeutics N.V. Uses of gamma delta t cell activating antibodies
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
JP2024546948A (ja) * 2021-12-15 2024-12-26 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド コンジュゲート、それらの組成物、及びそれらの関連する方法
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
EP4285926A1 (en) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
NL2032398B1 (en) 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4438624A1 (en) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Antibodies that bind nectin-4 and gamma-delta t cell receptors
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
AR132290A1 (es) 2023-04-05 2025-06-11 Genmab As Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3
AR133071A1 (es) 2023-06-30 2025-08-20 Genmab As ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
TW202519261A (zh) 2023-07-27 2025-05-16 荷蘭商拉法醫療公司 用於治療癌症之結合γ-δ T細胞受體之抗體
CN119816522B (zh) * 2023-08-18 2025-06-24 上海美雅珂生物技术有限责任公司 5t4抗体药物偶联物及其应用
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025158071A1 (en) 2024-01-26 2025-07-31 Sartorius Albumedix Limited Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction
CN118955647A (zh) * 2024-07-31 2024-11-15 西安交通大学医学院第一附属医院 Mdm2/mdmx抑制肽、组合物及制备方法与应用
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
EP4703468A1 (en) 2024-08-29 2026-03-04 Sartorius Albumedix Limited Methods and uses

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6009A (en) * 1849-01-09 Improvement in machines for gathering pea-vines
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4450103A (en) 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5753627A (en) 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
AU664030B2 (en) 1991-02-27 1995-11-02 Micromet Ag Serine-rich peptide linkers
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
FR2686620B1 (fr) 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
JPH08507680A (ja) 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
CN1074243A (zh) 1993-02-06 1993-07-14 北京中化生物技术研究所 白介素6-白介素2融合蛋白及其制法和用途
US5780594A (en) 1993-03-01 1998-07-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Biologically active protein fragments containing specific binding regions of serum albumin or related proteins
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5631158A (en) 1993-10-25 1997-05-20 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
AR008077A1 (es) 1996-07-26 1999-12-09 Talarico Salinas Laura Beatriz Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6191269B1 (en) 1997-05-30 2001-02-20 The Regents Of The University Of California Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
PT991619E (pt) 1997-06-23 2004-02-27 Upjohn Co Inibidores da adesao celular mediada pela alfa4beta1
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
US6171809B1 (en) 1998-01-29 2001-01-09 Packard Instrument Company Method and compositions for detecting luciferase biological samples
EP2363484A3 (en) 1998-04-03 2012-04-25 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
MXPA00011774A (es) 1998-05-28 2002-10-17 Biogen Inc Un nuevo inhibidor vla-4: ome pupa-v.
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
US6355678B1 (en) 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
HK1042434B (zh) 1998-10-16 2008-01-25 生物基因Ma公司 干扰素-β-1A的聚合物缀合物及其使用
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
JP3180906B2 (ja) 1998-11-12 2001-07-03 日本電気株式会社 磁気抵抗効果型複合ヘッドの製造方法
CA2362831C (en) 1999-02-18 2008-10-07 F. Hoffmann-La Roche Ag Thioamide derivatives
US8236159B2 (en) * 1999-04-13 2012-08-07 Applied Materials Inc. Electrolytic process using cation permeable barrier
US6265572B1 (en) 1999-04-20 2001-07-24 Hoffmann-La Roche Inc. Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
DK1265606T3 (da) 1999-08-13 2007-02-12 Biogen Idec Inc Celleadhæsionsinhibitorer
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
JP4788939B2 (ja) 1999-11-18 2011-10-05 味の素株式会社 新規フェニルアラニン誘導体
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
AP2002002565A0 (en) 1999-12-28 2002-06-30 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
WO2001070670A1 (en) 2000-03-23 2001-09-27 Ajinomoto Co., Inc. Novel phenylalanine derivative
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001089564A2 (en) 2000-05-19 2001-11-29 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
US6787636B1 (en) 2000-07-14 2004-09-07 New Century Pharmaceuticals, Inc. Modified serum albumin with reduced affinity for nickel and copper
US20040247565A1 (en) 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US7015216B2 (en) 2000-07-21 2006-03-21 Elan Pharmaceuticals, Inc. Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors
AU2001278986A1 (en) 2000-07-21 2002-02-05 Elan Pharmaceuticals, Inc. 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
CZ302653B6 (cs) 2000-08-18 2011-08-17 Ajinomoto Co., Inc. Fenylalaninové deriváty, alfa-4-integrinový antagonist, terapeutické cinidlo nebo preventivní cinidlo a farmaceutický prostredek obsahující tyto deriváty
JPWO2002022563A1 (ja) 2000-09-14 2004-01-22 東レ株式会社 ウレア誘導体及びそれを有効成分とする接着分子阻害剤
DE60122555T2 (de) 2000-09-25 2007-07-12 Toray Industries, Inc. Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
SK286991B6 (sk) 2001-02-22 2009-09-07 Celltech R&D Limited Fenylalanínenamidové deriváty, farmaceutický prostriedok obsahujúci tento derivát a použitie
ES2180416B1 (es) 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
EP1414471B1 (en) 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
JP4164871B2 (ja) 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
JPWO2003080611A1 (ja) 2002-03-22 2005-07-21 東レ株式会社 スピロ誘導体及びそれを有効成分とする接着分子阻害剤
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
GB0216571D0 (en) 2002-07-17 2002-08-28 Celltech R&D Ltd Chemical compounds
GB0216568D0 (en) 2002-07-17 2002-08-28 Celltech R&D Ltd Chemical compounds
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
WO2004082640A2 (en) 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
US7446125B2 (en) 2003-04-09 2008-11-04 Universidad Del Pais Vasco Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders
US7183092B2 (en) 2003-10-03 2007-02-27 Board Of Control Of Michigan Technological University Modified luciferase
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
JP2007536254A (ja) 2004-05-05 2007-12-13 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
TW200610754A (en) 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
US20060018859A1 (en) 2004-07-16 2006-01-26 Carter Daniel C Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at Cys 34
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
CN101072581A (zh) 2004-10-05 2007-11-14 健泰科生物技术公司 具有减少的毒性的治疗剂
JP2008526205A (ja) 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
EP1853309A4 (en) 2005-02-23 2008-10-22 Merrimack Pharmaceuticals Inc BISPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY
US20070243163A1 (en) 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
KR20090064453A (ko) 2006-09-14 2009-06-18 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
WO2008140493A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
US8343950B2 (en) * 2006-12-15 2013-01-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
ES2433424T3 (es) * 2008-08-15 2013-12-11 Merrimack Pharmaceuticals, Inc. Métodos y sistemas para predecir respuesta de células frente a un agente terapéutico
BRPI0921586A2 (pt) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
US9238080B2 (en) * 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
WO2013067355A1 (en) * 2011-11-04 2013-05-10 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
WO2014036520A1 (en) * 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents

Also Published As

Publication number Publication date
CN102282168A (zh) 2011-12-14
US20150191545A1 (en) 2015-07-09
US20110059076A1 (en) 2011-03-10
KR20110112301A (ko) 2011-10-12
US20170204192A1 (en) 2017-07-20
JP2012509259A (ja) 2012-04-19
JP5677972B2 (ja) 2015-02-25
WO2010059315A1 (en) 2010-05-27
US8927694B2 (en) 2015-01-06
US20120003221A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
BRPI0921586A2 (pt) articuladores de albumina de soro humana e conjugados destes
BRPI0911652A2 (pt) Ligantes de albumina sérica humana e seus conjugados
CY2021027I2 (el) Σκευασματα αντισωματων anti-cd20
BRPI0917000A2 (pt) proteínas conjugadas com eficácia in vivo prolongada
SI2126093T1 (sl) Izboljšanje priprave proteinov
SMT201500082B (it) Coniugati di oligosaccaride-proteina
BRPI0923283A2 (pt) conjugados terapêuticos de peptídeo e usos dos mesmos
EP1996700A4 (en) Cancerous disease modifying antibody 141205-05
EP2173377A4 (en) ANTIBODY ENDOSTATIN FUSION PROTEIN AND ITS VARIATIONS
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
EP2211885A4 (en) COMBINED THERAPY ASSOCIATING ANTIBODY-MEDICINAL CONJUGATES
SMT201600314B (it) Coniugati di proteina di coagulazione di sangue
EP2214711A4 (en) ANTI-RSV G PROTEIN ANTIBODY
BRPI0814252A2 (pt) Formulações de anticorpo
EP2265283A4 (en) Auristatin-DRUG-LINKER CONJUGATES
EP2207803A4 (en) Cd9-specific human antibodies
DK2046826T3 (da) Exendin-fusionsproteiner
DK3118220T3 (da) Protein
BRPI0921947A2 (pt) formulações de proteína terapêutica
BRPI0814971A2 (pt) Proteína
EP2084185A4 (en) HUMAN ANTIBODIES FOR NEUTRALIZING HUMAN METAPNEUMOVIRUS
EP1996699A4 (en) ANTIBODIES THAT MODIFY CANCER DISEASES
EP2044119A4 (en) ANTIBODIES THAT MODIFY CANCER DISEASES
EP2356145A4 (en) COMPLETE HUMAN ANTIBODIES AGAINST N-CADHERINE
EP2293815A4 (en) SYNERGISTIC IMMUNOGENIC FUSION PROTEIN POLYSACCHARIDE CONJUGATE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.